Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,529 across all filing types
Latest filing 2026-05-29 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 98% confidence The document is a notification of a transaction by a person discharging managerial responsibilities (a board member) involving restricted share units. This aligns with insider transactions by directors and executives. Therefore, it falls under Director's Dealing (DIRS).
2026-05-29 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 95% confidence The document is a company announcement disclosing transactions in the company’s shares by persons discharging managerial responsibilities and their closely associated persons (a PDMR notification). This falls squarely under insider dealings by directors and executives. Hence, it should be classified as Director’s Dealing (DIRS).
2026-05-29 English
Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)
Regulatory Filings
2026-05-26 Danish
Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)
Transaction in Own Shares Classification · 90% confidence The document is a company announcement detailing transactions executed under its share buy-back program, including number of shares repurchased, dates, prices, and accumulated totals. This matches the definition of Transaction in Own Shares (POS): a report of the company buying back its own shares.
2026-05-26 English
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
Regulatory Filings
2026-05-14 Danish
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
Transaction in Own Shares Classification · 92% confidence The document is a company announcement detailing the execution of transactions under its share buy-back program, including dates, share quantities, prices, and cumulative totals. It references the Market Abuse Regulation and provides a breakdown of treasury shares held post-transactions. This matches the definition for “Transaction in Own Shares” (POS), which covers reports of share repurchase activities.
2026-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.